Overview

DDP ip Combined With AG in PDAC With Peritoneal Metastasis

Status:
Recruiting
Trial end date:
2023-07-02
Target enrollment:
Participant gender:
Summary
intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Gemcitabine
Paclitaxel